DE69918089D1 - Btk inhibitoren und verfahren zur identifizierung und verwendung - Google Patents

Btk inhibitoren und verfahren zur identifizierung und verwendung

Info

Publication number
DE69918089D1
DE69918089D1 DE69918089T DE69918089T DE69918089D1 DE 69918089 D1 DE69918089 D1 DE 69918089D1 DE 69918089 T DE69918089 T DE 69918089T DE 69918089 T DE69918089 T DE 69918089T DE 69918089 D1 DE69918089 D1 DE 69918089D1
Authority
DE
Germany
Prior art keywords
identification
btk inhibitors
inhibitors
btk
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918089T
Other languages
English (en)
Other versions
DE69918089T2 (de
Inventor
Fatih M Uckun
Yaguo Zheng
Sutapa Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Cancer Center
Original Assignee
Parker Hughes Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/273,191 external-priority patent/US6303652B1/en
Application filed by Parker Hughes Cancer Center filed Critical Parker Hughes Cancer Center
Publication of DE69918089D1 publication Critical patent/DE69918089D1/de
Application granted granted Critical
Publication of DE69918089T2 publication Critical patent/DE69918089T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69918089T 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung Expired - Fee Related DE69918089T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8209498P 1998-04-17 1998-04-17
US82094P 1998-04-17
US09/273,191 US6303652B1 (en) 1998-08-21 1999-03-19 BTK inhibitors and methods for their identification and use
US273191 1999-03-19
PCT/US1999/008556 WO1999054286A2 (en) 1998-04-17 1999-04-19 Btk inhibitors and methods for their identification and use

Publications (2)

Publication Number Publication Date
DE69918089D1 true DE69918089D1 (de) 2004-07-22
DE69918089T2 DE69918089T2 (de) 2005-07-14

Family

ID=26767041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918089T Expired - Fee Related DE69918089T2 (de) 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung

Country Status (13)

Country Link
EP (1) EP1071658B1 (de)
JP (1) JP2002512216A (de)
KR (1) KR20010042804A (de)
AT (1) ATE269295T1 (de)
AU (1) AU3653099A (de)
CA (1) CA2328962A1 (de)
DE (1) DE69918089T2 (de)
ES (1) ES2222705T3 (de)
HU (1) HUP0102661A2 (de)
IL (1) IL139080A0 (de)
MX (1) MXPA00010150A (de)
NO (1) NO20005224L (de)
WO (1) WO1999054286A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
AU781986B2 (en) 1999-11-05 2005-06-23 Cytovia, Inc. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
AU4508601A (en) * 1999-11-30 2001-06-18 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2001236361A1 (en) * 2000-10-20 2002-05-06 Parker Hughes Institute Treatment of asthma with lfm analogues
EP1373554A2 (de) * 2000-10-23 2004-01-02 Bristol-Myers Squibb Company Modulatoren von brutons-tyrosinkinase, identifizierung und verwendung dazu
JP2004528311A (ja) * 2001-03-07 2004-09-16 テリック，インコーポレイテッド Ｆａｓ媒介アポトーシスの刺激剤としての置換ジアリールウレア
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
US20040152772A1 (en) * 2001-03-13 2004-08-05 Erich Eigenbrodt 1-butyric acid derivatives and the use thereof
EP1392683B1 (de) 2001-05-16 2009-12-02 Cytovia, Inc. Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel
EP1392283A4 (de) 2001-05-16 2004-10-20 Cytovia Inc Substituierte cumarine und chinoline als caspase-aktivatoren
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003027295A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of jak1
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN100349887C (zh) 2002-05-16 2007-11-21 西托维亚公司 取代的4－芳基－4h－吡咯并[2,3－h]色烯和类似物及其药物组合物和用途
EP1534666A1 (de) 2002-09-06 2005-06-01 Schebo Biotech AG Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
SG142305A1 (en) * 2004-10-19 2008-05-28 Aventis Pharma Inc Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP2010502751A (ja) * 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
EP2529621B1 (de) * 2006-09-22 2016-10-05 Pharmacyclics LLC Hammer der Bruton-Tyrosinkinase
DK2134374T3 (en) * 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
JP5479105B2 (ja) * 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
CA2724861A1 (en) * 2008-06-05 2009-12-10 Alembic Limited A process for preparing teriflunomide
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
MX2012011504A (es) * 2010-04-05 2013-01-18 Mannkind Corp Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
JP6307515B2 (ja) * 2012-11-28 2018-04-04 コーニング インコーポレイテッド 肝細胞機能の増強のための細胞培養培地
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2981264B1 (de) * 2013-04-02 2018-04-25 F.Hoffmann-La Roche Ag Brutons tyrosin kinase inhibitoren
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
EP2832358A1 (de) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmazeutisches Kit zur Verwendung bei der Behandlung von Darm- und kolorektalem Krebs
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CN105764896A (zh) 2013-09-30 2016-07-13 药品循环有限责任公司 布鲁顿氏酪氨酸激酶的抑制剂
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3079682A4 (de) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung eines lymphoplasmazytischen lymphoms
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
JP7305352B2 (ja) 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555685A1 (de) * 1975-12-11 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5723631A (en) * 1992-12-23 1998-03-03 Smithkline Beecham Corporation Coumarin derivatives as retroviral inhibitors
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5489697A (en) * 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
AU5259296A (en) * 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina

Also Published As

Publication number Publication date
WO1999054286A3 (en) 2000-05-04
ES2222705T3 (es) 2005-02-01
WO1999054286A2 (en) 1999-10-28
EP1071658B1 (de) 2004-06-16
NO20005224D0 (no) 2000-10-17
IL139080A0 (en) 2001-11-25
CA2328962A1 (en) 1999-10-28
ATE269295T1 (de) 2004-07-15
HUP0102661A2 (hu) 2001-11-28
KR20010042804A (ko) 2001-05-25
MXPA00010150A (es) 2002-05-14
JP2002512216A (ja) 2002-04-23
EP1071658A2 (de) 2001-01-31
NO20005224L (no) 2000-12-18
AU3653099A (en) 1999-11-08
DE69918089T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60007095D1 (de) Calanolide zur hemmung von btk
DE60125715D1 (de) Verfahren und testsysteme zur identifizierung von elite event gat-zm1 in biologischen proben
DE60214946D1 (de) Verfahren und System zur Bereitstellung von Informationen
ATE471374T1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE467301T1 (de) Verfahren und vorrichtung für gleichrangigen diensten
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
DE60206052D1 (de) System und verfahren zur bearbeitung von flugplandaten
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE60038328D1 (de) Gerät, Verfahren und Medium zur Informationsverarbeitung
DE60141671D1 (de) Vorrichtung, Verfahren und Programmprodukt zur Erfassung und Bereitstellung von Information
DE60309647D1 (de) System und Verfahren zur gesicherten Behandlung von Kontrollinformationen
DE60210265D1 (de) Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
EP1700120A4 (de) Marker für neuromyelitis optica
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
ATA1112001A (de) Verfahren zur tragekontrolle von regulierungen
DE60321824D1 (de) System und verfahren zur minimierung der modulationsinstabilität
DE50203510D1 (de) Verfahren zur erkennung und identifizierung von objekten
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE69925482D1 (de) Verfahren, einrichtung und gerät zur authentifizierung
DE60315575D1 (de) Verfahren und Vorrichtung zur Untersuchung von Oberflächen
DE60029039D1 (de) Verfahren, Vorrichtung und Computerprogramm zur Verschlüsselung von Computertelefonie
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee